Source: Virtual Congress 2020 – Impact in children and in adults with premorbid respiratory disease (acute and long-term)
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Harari (Milano (MI), Italy). ILD. Virtual Congress 2020 – Impact in children and in adults with premorbid respiratory disease (acute and long-term)

Member's Comments

No comment yet.

Related content which might interest you: Unclassifiable ILD Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Unclassifiable ILD Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Coexistent COPD and ILD Source: Eur Respir Monogr 2015; 69: 109-120 Year: 2015 Defining progression in non-IPF ILD Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Pulmonary fibrosis and ILD Source: Research Seminar 2013 - Optimising models for human lung diseases and drug development Year: 2013 COVID-19: Current Challenges in ILD Source: ERS webinar 2020: COVID-19: Current Challenges in ILD Year: 2020 Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003 Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Clinical case on ILD: a pulmonary case with many faces: not only interstitium Source: Annual Congress 2007 - Clinical Grand Round: an interactive session Year: 2007 Delay in diagnosis of interstitial lung diseases (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 IPF Source: Eur Respir Monogr 2017; 77: 199-223 Year: 2017 IPF Source: Eur Respir Monogr 2017; 77: 58-65 Year: 2017 Interstitial lung disease in CVID (GLILD): clinical presentation and comparison to CVID without ILD Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD) Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012